These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14707245)

  • 1. Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era.
    Allen SH; Brennan-Benson P; Nelson M; Asboe D; Bower M; Azadian B; Gazzard B; Stebbing J
    Postgrad Med J; 2003 Dec; 79(938):691-4. PubMed ID: 14707245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.
    Franzetti F; Grassini A; Piazza M; Degl'innocenti M; Bandera A; Gazzola L; Marchetti G; Gori A
    Infection; 2006 Feb; 34(1):9-16. PubMed ID: 16501896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long term survival after Rhodococcus equi pneumonia in a patient with human immunodeficiency virus infection in the era of highly active antiretroviral therapy: case report and review].
    Vladusić I; Krajinović V; Begovac J
    Acta Med Croatica; 2006 Jun; 60(3):259-63. PubMed ID: 16933840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome.
    Curran A; Falcó V; Crespo M; Martinez X; Ribera E; Villar del Saz S; Imaz A; Coma E; Ferrer A; Pahissa A
    HIV Med; 2008 Oct; 9(8):609-15. PubMed ID: 18557951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial community-acquired pneumonia in HIV-infected patients.
    Madeddu G; Laura Fiori M; Stella Mura M
    Curr Opin Pulm Med; 2010 May; 16(3):201-7. PubMed ID: 20154625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen.
    Le Moing V; Rabaud C; Journot V; Duval X; Cuzin L; Cassuto JP; Al Kaied F; Dellamonica P; Chêne G; Raffi F;
    HIV Med; 2006 May; 7(4):261-7. PubMed ID: 16630039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy.
    Jordano Q; Falcó V; Almirante B; Planes AM; del Valle O; Ribera E; Len O; Pigrau C; Pahissa A
    Clin Infect Dis; 2004 Jun; 38(11):1623-8. PubMed ID: 15156452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
    Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
    HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
    Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
    AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy.
    Antinori S; Ridolfo A; Fasan M; Magni C; Galimberti L; Milazzo L; Sollima S; Adorni F; Giuliani G; Galli M; Corbellino M; Parravicini C
    HIV Med; 2009 Jan; 10(1):6-11. PubMed ID: 19125961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T; Wei W; Amin K; Kazanjian P
    Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.